Author: Tavan Janvilisri
Publisher: Frontiers Media SA
ISBN: 2889630242
Category :
Languages : en
Pages : 131
Book Description
Clostridium difficile infection (CDI) is among the leading causes of infectious diarrhea among patients in hospitals. Multidrug resistance in C. difficile continues to plague antimicrobial chemotherapy of CDI, posing a major cause of concerns within healthcare and hospital environments. Hence, there is an urgent need for alternative therapeutic approaches for multidrug resistant C. difficile.
Alternative Therapeutic Approaches for Multidrug Resistant Clostridium difficile
Author: Tavan Janvilisri
Publisher: Frontiers Media SA
ISBN: 2889630242
Category :
Languages : en
Pages : 131
Book Description
Clostridium difficile infection (CDI) is among the leading causes of infectious diarrhea among patients in hospitals. Multidrug resistance in C. difficile continues to plague antimicrobial chemotherapy of CDI, posing a major cause of concerns within healthcare and hospital environments. Hence, there is an urgent need for alternative therapeutic approaches for multidrug resistant C. difficile.
Publisher: Frontiers Media SA
ISBN: 2889630242
Category :
Languages : en
Pages : 131
Book Description
Clostridium difficile infection (CDI) is among the leading causes of infectious diarrhea among patients in hospitals. Multidrug resistance in C. difficile continues to plague antimicrobial chemotherapy of CDI, posing a major cause of concerns within healthcare and hospital environments. Hence, there is an urgent need for alternative therapeutic approaches for multidrug resistant C. difficile.
Pneumonia Before Antibiotics
Author: Scott H. Podolsky
Publisher: JHU Press
ISBN: 0801889286
Category : Medical
Languages : en
Pages : 448
Book Description
“Uses [pneumonia] as a vehicle for examining the evolution of therapeutics in America between the ‘Golden Age of Microbiology’ and the ‘Age of Antibiotics.’”—Isis Focusing largely on the treatment of pneumonia in first half of the century with type-specific serotherapy, clinician-historian Scott H. Podolsky provides insight into the rise and clinical evaluation of therapeutic “specifics,” the contested domains of private practice and public health, and—as the treatment of pneumonia made the transition from serotherapy to chemotherapy and antibiotics—the tempo and mode of therapeutic change itself. Type-specific serotherapy, founded on the tenets of applied immunology, justified by controlled clinical trials, and grounded in a novel public ethos, was deemed revolutionary when it emerged to replace supportive therapeutics. With the advent of the even more revolutionary sulfa drugs and antibiotics, pneumonia ceased to be a public health concern and became instead an illness treated in individual patients by individual physicians. Podolsky describes the new therapeutics and the scientists and practitioners who developed and debated them. He finds that, rather than representing a barren era in anticipation of some unknown transformation to come, the first decades of the twentieth-century shaped the use of, and reliance upon, the therapeutic specific throughout the century and beyond. This intriguing study will interest historians of medicine and science, policymakers, and clinicians alike. “Podolsky’s scholarship is awesome, and his grasp of the philosophical and sociologic context of the issues considered make this an important work.” —New England Journal of Medicine “This thoroughly documented, carefully written book is a landmark analysis . . . It should be read by everyone who is involved in research and therapeutic development.” —JAMA
Publisher: JHU Press
ISBN: 0801889286
Category : Medical
Languages : en
Pages : 448
Book Description
“Uses [pneumonia] as a vehicle for examining the evolution of therapeutics in America between the ‘Golden Age of Microbiology’ and the ‘Age of Antibiotics.’”—Isis Focusing largely on the treatment of pneumonia in first half of the century with type-specific serotherapy, clinician-historian Scott H. Podolsky provides insight into the rise and clinical evaluation of therapeutic “specifics,” the contested domains of private practice and public health, and—as the treatment of pneumonia made the transition from serotherapy to chemotherapy and antibiotics—the tempo and mode of therapeutic change itself. Type-specific serotherapy, founded on the tenets of applied immunology, justified by controlled clinical trials, and grounded in a novel public ethos, was deemed revolutionary when it emerged to replace supportive therapeutics. With the advent of the even more revolutionary sulfa drugs and antibiotics, pneumonia ceased to be a public health concern and became instead an illness treated in individual patients by individual physicians. Podolsky describes the new therapeutics and the scientists and practitioners who developed and debated them. He finds that, rather than representing a barren era in anticipation of some unknown transformation to come, the first decades of the twentieth-century shaped the use of, and reliance upon, the therapeutic specific throughout the century and beyond. This intriguing study will interest historians of medicine and science, policymakers, and clinicians alike. “Podolsky’s scholarship is awesome, and his grasp of the philosophical and sociologic context of the issues considered make this an important work.” —New England Journal of Medicine “This thoroughly documented, carefully written book is a landmark analysis . . . It should be read by everyone who is involved in research and therapeutic development.” —JAMA
Phage Therapy: Past, Present and Future
Author: Stephen T. Abedon
Publisher: Frontiers Media SA
ISBN: 2889452514
Category :
Languages : en
Pages : 394
Book Description
Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.
Publisher: Frontiers Media SA
ISBN: 2889452514
Category :
Languages : en
Pages : 394
Book Description
Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d’Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.
Guideline for Isolation Precautions in Hospitals
Author: Julia S. Garner
Publisher:
ISBN:
Category : Cross infection
Languages : en
Pages : 92
Book Description
Publisher:
ISBN:
Category : Cross infection
Languages : en
Pages : 92
Book Description
Treating Infectious Diseases in a Microbial World
Author: National Research Council
Publisher: National Academies Press
ISBN: 0309180686
Category : Medical
Languages : en
Pages : 102
Book Description
Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.
Publisher: National Academies Press
ISBN: 0309180686
Category : Medical
Languages : en
Pages : 102
Book Description
Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.
Clostridium Difficile
Author: Rial D. Rolfe
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 434
Book Description
Despite the tremendous progress made during the last few years in understanding the pathogenesis, epidemiology, diagnosis, and treatment of Clostridium difficile-associated intestinal disease, many extremely important and fundamental questions remain to be answered. The objectives of this book are to summarize the available information regarding Clostridium difficile and its role in intestinal disease and to serve as a basis for future investigations in this challenging area. Clostridium difficile: its role in Intestinal Disease. An excellent volume that should appeal not only to the devotee of C difficile but to all gastroenterologists and microbiologists, this will not languish on my library shelves like so many other books I have reviewed. It will be regularly thumbed. --R.H. George, consultant microbiologist, Children's Hospital, Birmingham Clostridium difficile: Its Role in Intestinal disease. The book is well written and informative; it has a vast amount of information packed in it...this book would be a welcome addition to the researchers and clinicians interested in C difficile-associated intestinal diseases. --Edward Balish, University of Wisconsin Medical School
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 434
Book Description
Despite the tremendous progress made during the last few years in understanding the pathogenesis, epidemiology, diagnosis, and treatment of Clostridium difficile-associated intestinal disease, many extremely important and fundamental questions remain to be answered. The objectives of this book are to summarize the available information regarding Clostridium difficile and its role in intestinal disease and to serve as a basis for future investigations in this challenging area. Clostridium difficile: its role in Intestinal Disease. An excellent volume that should appeal not only to the devotee of C difficile but to all gastroenterologists and microbiologists, this will not languish on my library shelves like so many other books I have reviewed. It will be regularly thumbed. --R.H. George, consultant microbiologist, Children's Hospital, Birmingham Clostridium difficile: Its Role in Intestinal disease. The book is well written and informative; it has a vast amount of information packed in it...this book would be a welcome addition to the researchers and clinicians interested in C difficile-associated intestinal diseases. --Edward Balish, University of Wisconsin Medical School
Disease Control Priorities, Third Edition (Volume 6)
Author: King K. Holmes
Publisher: World Bank Publications
ISBN: 1464805253
Category : Medical
Languages : en
Pages : 1027
Book Description
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.
Publisher: World Bank Publications
ISBN: 1464805253
Category : Medical
Languages : en
Pages : 1027
Book Description
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.
Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and Their Components
Author: Mahendra Rai
Publisher: Academic Press
ISBN: 0124017088
Category : Science
Languages : en
Pages : 291
Book Description
Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and their Components offers scientists a single source aimed at fighting specific multidrug-resistant (MDR) microorganisms such as bacteria, protozoans, viruses and fungi using natural products. This essential reference discusses herbal extracts and essential oils used or under investigation to treat MDR infections, as well as those containing antimicrobial activity that could be of potential interest in future studies against MDR microorganisms. The need to combat multidrug-resistant microorganisms is an urgent one and this book provides important coverage of mechanism of action, the advantages and disadvantages of using herbal extracts, essential oils and their components and more to aid researchers in effective antimicrobial drug discovery - Addresses the need to develop safe and effective approaches to coping with resistance to all classes of antimicrobial drugs - Provides readers with current evidence-based content aimed at using herbal extracts and essential oils in antimicrobial drug development - Includes chapters devoted to the activity of herbal products against herpes, AIDS, tuberculosis, drug-resistant cancer cells and more
Publisher: Academic Press
ISBN: 0124017088
Category : Science
Languages : en
Pages : 291
Book Description
Fighting Multidrug Resistance with Herbal Extracts, Essential Oils and their Components offers scientists a single source aimed at fighting specific multidrug-resistant (MDR) microorganisms such as bacteria, protozoans, viruses and fungi using natural products. This essential reference discusses herbal extracts and essential oils used or under investigation to treat MDR infections, as well as those containing antimicrobial activity that could be of potential interest in future studies against MDR microorganisms. The need to combat multidrug-resistant microorganisms is an urgent one and this book provides important coverage of mechanism of action, the advantages and disadvantages of using herbal extracts, essential oils and their components and more to aid researchers in effective antimicrobial drug discovery - Addresses the need to develop safe and effective approaches to coping with resistance to all classes of antimicrobial drugs - Provides readers with current evidence-based content aimed at using herbal extracts and essential oils in antimicrobial drug development - Includes chapters devoted to the activity of herbal products against herpes, AIDS, tuberculosis, drug-resistant cancer cells and more
CDC Yellow Book 2018: Health Information for International Travel
Author: Centers for Disease Control and Prevention CDC
Publisher: Oxford University Press
ISBN: 0190628634
Category : Medical
Languages : en
Pages : 705
Book Description
THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.
Publisher: Oxford University Press
ISBN: 0190628634
Category : Medical
Languages : en
Pages : 705
Book Description
THE ESSENTIAL WORK IN TRAVEL MEDICINE -- NOW COMPLETELY UPDATED FOR 2018 As unprecedented numbers of travelers cross international borders each day, the need for up-to-date, practical information about the health challenges posed by travel has never been greater. For both international travelers and the health professionals who care for them, the CDC Yellow Book 2018: Health Information for International Travel is the definitive guide to staying safe and healthy anywhere in the world. The fully revised and updated 2018 edition codifies the U.S. government's most current health guidelines and information for international travelers, including pretravel vaccine recommendations, destination-specific health advice, and easy-to-reference maps, tables, and charts. The 2018 Yellow Book also addresses the needs of specific types of travelers, with dedicated sections on: · Precautions for pregnant travelers, immunocompromised travelers, and travelers with disabilities · Special considerations for newly arrived adoptees, immigrants, and refugees · Practical tips for last-minute or resource-limited travelers · Advice for air crews, humanitarian workers, missionaries, and others who provide care and support overseas Authored by a team of the world's most esteemed travel medicine experts, the Yellow Book is an essential resource for travelers -- and the clinicians overseeing their care -- at home and abroad.
Challenges to Tackling Antimicrobial Resistance
Author: Michael Anderson
Publisher: Cambridge University Press
ISBN: 1108799450
Category : Health & Fitness
Languages : en
Pages : 273
Book Description
An accessible overview of the challenges in tackling AMR, and the economic and policy responses of the 'One Health' approach. It will appeal to policy-makers seeking to strengthen national and local polices tackling AMR, as well as students and academics who want an overview of the latest scientific evidence regarding effective AMR policies.
Publisher: Cambridge University Press
ISBN: 1108799450
Category : Health & Fitness
Languages : en
Pages : 273
Book Description
An accessible overview of the challenges in tackling AMR, and the economic and policy responses of the 'One Health' approach. It will appeal to policy-makers seeking to strengthen national and local polices tackling AMR, as well as students and academics who want an overview of the latest scientific evidence regarding effective AMR policies.